M
M Bernard
Researcher at McGill University
Publications - 5
Citations - 333
M Bernard is an academic researcher from McGill University. The author has contributed to research in topics: Methylprednisolone & Quality of life. The author has an hindex of 5, co-authored 5 publications receiving 262 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy
Luigi Bartalena,G. E. Krassas,Wilmar M. Wiersinga,Claudio Marcocci,Mario Salvi,Chantal Daumerie,C Bournaud,M Stahl,L. Sassi,Giovanni Veronesi,Claudio Azzolini,Kostas G. Boboridis,M. P. Mourits,M. R. Soeters,L Baldeschi,Marco Nardi,Nicola Currò,Antonella Boschi,M Bernard,G von Arx +19 more
TL;DR: A multicenter, randomized, double-blind trial to determine efficacy and safety of three doses of i.v. methylprednisolone for Graves' orbitopathy, finding that the 7.47-g dose provides short-term advantages over lower doses, but this benefit is transient and associated with slightly greater toxicity.
Journal ArticleDOI
Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?
Luigi Bartalena,Giovanni Veronesi,G. E. Krassas,W. M. Wiersinga,Claudio Marcocci,Michele Marinò,Mario Salvi,Chantal Daumerie,C Bournaud,M Stahl,L. Sassi,Claudio Azzolini,Kostas G. Boboridis,M. P. Mourits,M. R. Soeters,L Baldeschi,Marco Nardi,Nicola Currò,Antonella Boschi,M Bernard,G von Arx,Petros Perros,George J. Kahaly +22 more
TL;DR: Patients who deteriorate at 6 weeks after iv GCs are unlikely to benefit from continuing ivGCs, and they may continue ivGC treatment, or, alternatively, possibly stop ivGCS and be switched to a second-line treatment.
Journal ArticleDOI
Asymmetry indicates more severe and active disease in Graves' orbitopathy: results from a prospective cross-sectional multicentre study.
Petros Perros,Miloš Žarković,Grigorios Panagiotou,Claudio Azzolini,Göksun Ayvaz,L Baldeschi,Luigi Bartalena,Antonella Boschi,Marco Nardi,Thomas Heiberg Brix,Danila Covelli,Chantal Daumerie,Anja Eckstein,Nicole Fichter,Slavica Ćirić,L. Hegedüs,George J. Kahaly,Onur Konuk,Jürg Lareida,Onyebuchi E. Okosieme,Marenza Leo,Lemonia Mathiopoulou,Lucy Clarke,Francesca Menconi,Daniel S Morris,Jacques Orgiazzi,Susanne Pitz,Mario Salvi,I. Muller,Miroslav Knežević,W. M. Wiersinga,Nicola Currò,Colin M. Dayan,Claudio Marcocci,Michele Marinò,Lars Möller,Simon H. S. Pearce,Fusun Balos Toruner,M Bernard +38 more
TL;DR: Older age, lower female to male ratio, more severe, and more active disease cluster around asymmetric Graves’ orbitopathy, asymmetry appears to be a marker of more severe and moreactive disease than other presentations.
Journal ArticleDOI
Failure to Detect Complement-Mediated Antibody-Dependent Cytotoxicity Against Human Orbital Tissue Cells in the Serum of Patients with Thyroid-Associated Ophthalmopathy
TL;DR: Sera from patients with TAO, most of which were shown to be positive in ADCC against eye muscle cell targets, were tested for complement-mediated antibody-dependent cytotoxicity (CMAC) against human and pig eye muscle cells, human (abdominal) skeletal muscle cells and human orbital fibroblasts, in 51Cr release assays.
Efficacy and safety of three different cumulative doses of intraveneous methylprednisolone for moderate to severe and active Graves’ orbitopathy.
Laura Bartalena,G. E. Krassas,W. M. Wiersinga,Mario Salvi,Chantal Daumerie,C Bournaud,M Stahl,L. Sassi,Giovanni Veronesi,Claudio Azzolini,Kg Boboridis,M. P. Mourits,Soeters,L Baldeschi,Nicola Currò,Antonella Boschi,M Bernard,G von Arx +17 more